Cagrilintide
vs Retatrutide.
Compare Cagrilintide vs Retatrutide by peptide identity, amylin versus triple-agonist mechanism, trial results, Phase 3 programs, side effects, and FDA status.
Also searched as Cagrilintide peptide vs Retatrutide · AM833 vs LY3437943 · amylin vs triple agonist
Cagrilintide vs Retatrutide: What is the difference?
Cagrilintide and retatrutide are different investigational once-weekly peptides, and no randomized head-to-head trial has compared them. Cagrilintide is a long-acting amylin analogue now studied alone in the Phase 3 RENEW program. It is also the amylin component of CagriSema, but evidence for that combination cannot be assigned to cagrilintide alone. Retatrutide is a synthetic peptide designed to activate GIP, GLP-1, and glucagon receptors, with Phase 3 TRIUMPH results now reported. Separate trials cannot establish which program is more effective, safer, more convenient, or more sustainable for an individual. Neither drug is FDA approved, and FDA states that neither cagrilintide nor retatrutide can be used in compounding under federal law.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Cagrilintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 52 matched NCT records
- Sponsor
- Novo Nordisk
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Cagrilintide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Cagrilintide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 10
- Results posted
- 2
- Recruiting site observations
- 170
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Answer the question without inventing a winner.
Each answer keeps route, mechanism, development stage, and trial result attached to the evidence that produced the fact.
Is Cagrilintide better than Retatrutide?
No randomized trial establishes standalone Cagrilintide or Retatrutide as better. Cagrilintide is an amylin analogue, while Retatrutide activates GIP, GLP-1, and glucagon receptors. The commonly compared 11.8% and 28.3% findings came from separate interventions, protocols, durations, populations, and estimands. CagriSema's combination results cannot be reassigned to Cagrilintide alone.
Is Cagrilintide the same as CagriSema?
No. Cagrilintide is one investigational long-acting amylin analogue. CagriSema is a fixed-dose combination containing Cagrilintide plus Semaglutide. The standalone and combination arms have different active regimens, results, trial programs, and regulatory paths. Treating the names as interchangeable overstates Cagrilintide monotherapy evidence and can misidentify online listings.
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT03856047 · NCT05567796 · NCT07220642 · NCT07220759
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
Searchers commonly compare an amylin-pathway peptide with a triple receptor agonist by using the largest reported weight-loss percentage, side-effect summaries, or the number of receptors involved. That shortcut mixes standalone cagrilintide with CagriSema and treats unrelated trials as though participants were randomized between the two drugs. A useful answer must resolve molecular identity first, distinguish standalone and combination evidence, and keep every result attached to its protocol, population, dose strategy, duration, estimand, placebo response, and regulatory status.
| Field | Cagrilintide | Retatrutide | How to interpret it |
|---|---|---|---|
| Molecular identity | Long-acting peptide amylin analogue, also known by the development code AM833 | Synthetic peptide triple agonist, also known by the development code LY3437943 | Both are peptides, but their sequences, clinical materials, receptor strategies, and development records are not interchangeable. |
| Receptor strategy | Amylin receptor agonism | GIP, GLP-1, and glucagon receptor agonism | Different receptor designs explain different development hypotheses, but receptor count cannot establish clinical superiority. |
| Weight evidence anchor | 11.8% mean change at week 68 versus 2.3% with placebo in the REDEFINE 1 monotherapy arm | 28.3% mean change at week 80 versus 2.2% with placebo for 12 mg in TRIUMPH-1 | The headline percentages answer different randomized questions and cannot be treated as a direct effect estimate. |
| Phase 3 path | Standalone RENEW program plus the separate CagriSema combination program | TRIUMPH Phase 3 program with obesity results reported | Program maturity and study context differ, and CagriSema evidence does not become cagrilintide monotherapy evidence. |
| Safety evidence context | Adverse events reported within cagrilintide and CagriSema protocols must remain separated | Adverse events reported within TRIUMPH protocols and retatrutide dose groups | Separate study summaries cannot establish fewer side effects, better tolerability, or individual suitability. |
| Current US status | Investigational, not FDA approved, and not permitted for compounding under federal law | Investigational, not FDA approved, and not permitted for compounding under federal law | Neither name identifies an approved pharmacy product, valid prescription label, retail price, or verified online supply route. |
Why the headline numbers do not name a winner.
In the cagrilintide monotherapy arm of REDEFINE 1, the trial-product estimand reported 11.8% mean weight loss at week 68 versus 2.3% with placebo. Lilly reported 28.3% mean weight loss at week 80 for 12 mg retatrutide versus 2.2% with placebo under an efficacy estimand in TRIUMPH-1. These figures came from separate sponsors, protocols, populations, phases, dose plans, durations, estimands, and placebo responses. Subtracting the percentages, dividing them into weekly rates, or assigning CagriSema results to cagrilintide would create comparative evidence that does not exist.
Keep the comparison honest.
- 01
Keep standalone cagrilintide, fixed-dose CagriSema, and retatrutide evidence attached to their exact randomized intervention and protocol.
- 02
Do not subtract 68-week and 80-week results, convert them into weekly rates, or interpret receptor count as comparative efficacy or safety.
- 03
Treat both programs as investigational and keep online listings separate from sponsor clinical material, FDA approval, and lawful pharmacy supply.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →